Donaghy M, Mills K R, Boniface S J, Simmons J, Wright I, Gregson N, Jacobs J
Department of Clinical Neurology, Radcliffe Infirmary, Oxford, UK.
J Neurol Neurosurg Psychiatry. 1994 Jul;57(7):778-83. doi: 10.1136/jnnp.57.7.778.
Within one month of starting oral prednisolone treatment weakness unexpectedly increased in four patients aged 34 to 75 years with purely motor forms of acquired chronic demyelinating neuropathy. By contrast, steroids produced the expected improvement in 11 other patients with symmetric sensorimotor chronic inflammatory demyelinating polyneuropathy. Two of the patients with purely motor demyelinating neuropathy were subsequently treated with high dose IVIg (0.4 g/kg/day for five days) with prompt improvements in strength measurements and motor nerve conduction. Thus IVIg seems to be the treatment of choice and steroids should be used with extreme caution, if at all, in patients with purely motor forms of acquired demyelinating polyneuropathy.
在开始口服泼尼松龙治疗的一个月内,4例年龄在34至75岁之间、患有单纯运动型获得性慢性脱髓鞘性神经病的患者意外出现肌无力加重。相比之下,类固醇使另外11例患有对称性感觉运动性慢性炎症性脱髓鞘性多发性神经病的患者出现了预期的改善。随后,2例单纯运动性脱髓鞘性神经病患者接受了大剂量静脉注射免疫球蛋白治疗(0.4 g/kg/天,共5天),肌力测量和运动神经传导迅速改善。因此,静脉注射免疫球蛋白似乎是首选治疗方法,对于患有单纯运动型获得性脱髓鞘性多发性神经病的患者,类固醇应极其谨慎使用,甚至根本不使用。